

In the name of God



Department of Internal Medicine  
**Shiraz E-Medical Journal**  
Vol. 7, No. 4, October 2006

<http://semj.sums.ac.ir/vol7/oct2006/hsp.htm>

## **Development of Henoch\_Schoenlein Vasculitis Following Ranitidine Administration in a Geriatric Patient.**

Sagheb MM\*, Sharifian M\*\*, Moini M<sup>Δ</sup>, Ghotbi Sh<sup>±</sup>.

\* Assistant Professor, Section of Nephrology, Department of Medicine, \*\* Medical Student , Δ Clinical fellow in Gastroenterology, Shiraz University of Medical Sciences, Shiraz, Iran, and ± Assistant Professor, Department of Obstetrics and Gynecology, Fasa Medical School Fasa, Iran.

Correspondence: Dr. MM Sagheb, Department of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, Telephone : +98(711) 626-1089, E-mail: [saghebm@sums.ac.ir](mailto:saghebm@sums.ac.ir)

Received for Publication: April 18, 2006, Accepted for Publication: August 15, 2006.

---

### **Abstract:**

Henoch\_Schoenlein Vasculitis following drug administration is not so common. Here, a case of Henoch\_Schoenlein Vasculitis caused by Ranitidine and Naproxen is described which presented with fever, vomiting bloody diarrhea, palpable purpura and azotemia. Histology of the skin showed leukocytoclastic vasculitis of superficial vessels and direct immunofluorescence revealed immunoglobulin A (IgA) in superficial dermal vessels and so confirmed the diagnosis. The patient was treated with Ranitidine discontinuation and Prednisone administration. A short review of literature is also made.

---

**Key Words: Henoch\_Schoenlein Vasculitis, Ranitidine, Naproxen.**

## Introduction:

Henoch-Schönlein purpura (HSP) is a self-limited systemic vasculitis. It is the most common systemic vasculitis of childhood and is characterized by a tetrad of clinical manifestations that vary in their presence and order of presentation. Adult patients with HSP present with the same clinical manifestations as seen in children<sup>(1)</sup>.

In 1990, the American College of Rheumatology Classification established criteria to classify vasculitides including HSP<sup>(2)</sup>. Based upon these criteria, the diagnosis of HSP required the following: Palpable purpura without thrombocytopenia and coagulopathy, Age at onset 20 years, Gastrointestinal bleeding, Biopsy which showed granulocytes around arterioles and venules. Two or more of the criteria had a sensitivity and specificity of approximately 90 percent in separating adult patients with HSP from those with other causes of vasculitis<sup>(3)</sup>. There are case reports about development of HSP in patients with ranitidine administration.<sup>(4, 5)</sup>

We describe here a case of henoch-schoeinlien purpura after ranitidine consumption.

## Case Presentation:

A 74 year old man was admitted with vomiting and bloody diarrhea. He was well until 2 weeks before admission when due to musculoskeletal pain received naproxen and ranitidine and after 8 days developed abdominal pain, bloody diarrhea, joint pain, general malaise and purpuric rashes on lower

extremities and buttock. He discontinued his medication including ranitidine and naproxen and symptoms were removed after one week. His dyspepsia continued so he started ranitidine again. While He was taking ranitidine alone for about 5 days he developed nausea vomiting, bloody diarrhea, joint pain and purpuric rash.

On admission the patient was febrile (38.1 c ), blood pressure, heart rate and respiratory rate were within normal range. Conjunctiva was pale, lungs were auscultated symmetrically clear bilaterally. Heart sound was normal. Abdomen was soft without any organomegaly but with mild diffuse tenderness. Multiple round, confluent, purpuric lesions with some area of residual pigmentation was seen on both upper and lower extremities and buttock.

Laboratory examination revealed severe azotemia (BUN:116 mg/dl, Cr: 6.5mg/dl). Urinalysis showed proteinuria of 0.9 g/24 h and microscopic hematuria. Urine culture was negative. C reactive protein was 96mg/dl. Hemoglobin was 8.6 mg/dl, leukocyte count was 12000/mL and platelet was 450000/mL. Prothrombin time and partial thromboplastin time were normal. Antistreptolysin O, antinuclear antibodies, anticardiolipin antibody, antinutrophil cytoplasmic antibody, cryoglobulins, and hepatitis B, C and HIV serologies were all negative. Kidney sonography showed increase of cortical echogenecity of both kidneys in favor of parenchymal damage. Histology of the skin showed leukocytoclastic vasculitis of superficial vessels and direct immunofluorescence revealed immunoglobulin A (IgA) in superficial dermal vessels.

Ranitidine was discontinued and prednisone (1 mg/kg/day) was started and the arthralgia, hematochezia, and eruption resolved over the next 7 days. Renal function gradually improved and patient did not need hemodialysis.

He was discharged while was on prednisone and omeprazole.

## Discussion:

The underlying cause of HSP is unknown. It has been postulated that HSP is an immune-mediated vasculitic disorder that is triggered by an immunoglobulin A (IgA) dominated response to an infection or chemical antigen. Drug induced hypersensitivity vasculitis and HSP are diseases that were reported with respiratory tract and intestinal infection, food allergy, insect bites, immunization and various drugs such as: Ranitidine (4, 5), Acetaminophen codeine (6,7), Etanercept (8), Clarithromycin (9), Propylthiouracil (10), Metoclopramide (11), Carbidopa/levodopa (12), Angiotensin converting enzyme inhibitors (13, 14), Co-dydramol (15), Ampicillin and amoxicillin

(16, 17), NSAID, Diclofenac, Piroxicam and Naproxen (18, 19, 20), Streptokinase (21, 22), Calcium channel blockers (23), Quinidine (24). Histologic findings in skin biopsy of this patient were in favor of hypersensitivity vasculitis and also a clinical diagnosis of HSP could be made based on features characteristics of the syndrome. This patient's problem occurred while was taking both naproxen and ranitidine and after discontinuation of these medication his purpuric rash and other symptoms disappeared.

Hyper sensitivity vasculitis was reported with both naproxen and ranitidine but in this patient after reconsumption of ranitidine alone his purpuric rash, arthritis and bloody diarrhea reappeared thus the relapse of clinical symptoms on rechallenge with ranitidine, strongly suggest that ranitidine was causally related to the acute Henoch-Schonlein Purpura.

Upon rechallenge renal involvement is more likely to occur and to be severe in this adult patient.

Adults are at increased risk for developing significant renal involvement requiring more aggressive therapy. (25)

## References:

1- Blanco, R, Martinez-Taboada, VM, Rodriguez-Valverde, V, et al. Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. *Arthritis Rheum* 1997; 40:859.

2- Mills, JA, Michel, BA, Bloch, DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. *Arthritis Rheum* 1990; 33:1114.

3- Calabrese, LH, Michel, BA, Bloch, DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. *Arthritis Rheum* 1990; 33:1108.

4- Prajapati C, Casson IF, Henoch-Schonlein purpura associated with ranitidine. *Int J Clin Pract*. 1997 Jun;51(4):251

5- Glazunov EN, Nevolina IA, Seregin VA, Serova LS, Demko MV. Vestn Khir Im I I Grek, .The development of hemorrhagic vasculitis (Schonlein-Henoch disease) in a patient with a chronic stomach ulcer against a background of Sostril (ranitidine hydrochloride) therapy, *Vestn Khir Im I I Greg*, 1994 Jan-Feb;152(1-2):102-3.

6- Santoro D, Stella M, Castellino S, Henoch-Schonlein purpura associated with acetaminophen and codeine. *Clin Nephrol*. 2006 Aug;66(2):131-4.

- 7- Genta M, Duffy TN, Moll S, Martin PY, Gabay C, Henoch Schonlein purpura following etanercept treatment of rheumatoid arthritis. *Clin Exp Rheumatol*. 2006 Mar-Apr;24(2 Suppl 41):S106
- 8- Borrás-Blasco J, Enriquez R, Amoros F, Cabezuelo JB, Navarro-Ruiz A, Henoch-Schonlein purpura associated with clarithromycin. Case report and review of literature. *Int J Clin Pharmacol Ther*. 2003 May;41(5):213-6.
- 9- Wang LH, Tsai MJ, Tsai WY, Lee JS, Chiang BL, Propylthiouracil-induced antineutrophil cytoplasm antibody-positive anaphylactoid purpura-like vasculitis--a case report., *J Formos Med Assoc*. 2000 Aug;99(8):642-5
- 10- Goad JA, Reversible nonthrombocytopenic palpable purpura associated with metoclopramide. *Ann Pharmacother*. 1999 Jan;33(1):35-7.
- 11- Niedermaier G, Briner V, Henoch-Schonlein syndrome induced by carbidopa/levodopa.. *Lancet*. 1997 Apr 12;349(9058):1071-2.
- 12- Jensen ON, Ahlquist P, Schoenlein-Henoch purpura in a geriatric patient after captopril therapy. *Ugeskr Laeger*. 1996 Aug 26;158(35):4926-7
- 13- Neumann J, Andrassy K, Walter-Sack I, Berg PA, Henoch-Schoenlein purpura and angiotensin-converting enzyme inhibitors. *Nephron*. 1994;67(1):117.
- 14- Moots RJ, Keeling PJ, Morgan SH, Adult Schonlein-Henoch purpura after enalapril, *Lancet*. 1992 Aug 1;340(8814):304-5.
- 15- Richards AJ, Lindley DC., Henoch-Schonlein purpura associated with co-dydramol., *Br J Rheumatol*. 1987 Feb;26(1):65.
- 16- Wakefield IR, Hunter DA, Antibiotic associated henoch-schonlein purpuras syndrome . *br j clin pract* 1988 ;42:525-526
- 17- Beeching NJ, Gruer LD, et. al., A case of Henoch-Schonlein purpura syndrome following oral ampicillin. *J Antimicrob Chemother*. 1982 Dec;10(6):479-82.
- 18- Goebel KM, Mueller-Brodmann W. Reversible overt nephropathy with Henoch-Schonlein purpura due to piroxicam. *Br Med J (Clin Res Ed)*. 1982 Jan 30;284(6312):311-2
- 19- Escudero A, Lucas E, Vidal JB, Sanchez-Guerrero I, Martinez A, Illan F, Ramos, Drug-related Henoch-Schonlein Purpura. *J. Allergol Immunopathol (Madr)*. 1996 Jan-Feb;24(1):22-4.
- 20- Schapira D, Balbir-Gurman A, Nahir AM, Naproxen-induced leukocytoclastic vasculitis., *Clin Rheumatol*. 2000;19(3):242-4
- 21- Zilliox AP, Domoto DT, Hutcheson PS, Tsai CC, Slavin RG, Henoch-Schoenlein purpura due to streptokinase. *J Clin Immunol*. 1993 Nov;13(6):415-23.
- 22- Stam F, Stehouwer CD., Henoch-Schonlein purpura following treatment with streptokinase, *Ned Tijdschr Geneesk*. 1992 Nov 21;136(47):2336-8
- 23- Kuo M, Winiarski N, Garella S., Nonthrombocytopenic purpura associated sequentially with nifedipine and diltiazem., *Ann Pharmacother*. 1992 Sep;26(9):1089-90.
- 24- Aviram A., Henoch-Schonlein syndrome associated with quinidine., *JAMA*. 1980 Feb 1;243(5):432-3.
- 25- Pillebout, E, Thervet, E, Hill, G, et al. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. *J Am Soc Nephrol* 2002; 13:1271.